The pharma company said the drug combined with eltrombopag demonstrated a significant improvement in time to treatment ...

Packaged breads and refined grain products may increase the odds of developing IBD, while minimally processed fresh bread and ...

European shares were broadly flat on Monday, as investors refrained from making big bets ahead of a key U.S. inflation data, ...

The Canadian miner posted better-than-forecast results, but booked a $1 billion loss against its Mali operations. The company ...

Patients with psoriasis have significantly more difficulty sleeping, particularly in new environments, than matched ...

Novartis announces positive results from VAYHIT2 phase III trial of ianalumab plus eltrombopag in patients with primary immune thrombocytopenia: Basel Wednesday, August 13, 2025, ...

Novartis' ianalumab plus eltrombopag significantly extended treatment response and improved platelet counts in a Phase 3 ...

A mere 24 hours after Novartis' ianalumab hit the mark in two phase 3 trials in Sjogren's syndrome, the drug has delivered ...

A day after posting a pair of phase 3 wins for the tricky indication of Sjögren's syndrome, the Swiss pharma has unveiled a ...

Novartis may have abandoned one Sjögren's syndrome asset this year, but it looks like the drugmaker has a winner on its hands ...

Novartis' mAb ianalumab helped maintain safe platelet levels for a prolonged period, reducing patient reliance on hospital trips.

Roche (RHHBY) and Novartis (NVS) are scheduled to meet with Swiss officials this week amid U.S. tariff threats on pharma ...